Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials

BACKGROUND: Anti-PD-1/PD-L1 antibody therapy is a promising clinical treatment for nonsmall-cell lung cancer (NSCLC). However, whether anti-PD-1/PD-L1 antibody therapy can provide added benefits for heavily pretreated patients with advanced NSCLC and whether the efficacy of anti-PD-1/PD-L1 antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Guo-Wu, Xiong, Ye, Chen, Si, Xia, Fan, Li, Qiang, Hu, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008560/
https://www.ncbi.nlm.nih.gov/pubmed/27583876
http://dx.doi.org/10.1097/MD.0000000000004611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008560/
https://www.ncbi.nlm.nih.gov/pubmed/27583876
http://dx.doi.org/10.1097/MD.0000000000004611

Ejemplares similares